IGFBP2, His, Cynomolgus
IGFBP2, His, Cynomolgus

The purity of IGFBP2, His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

IGFBP2, His, Cynomolgus

IGFBP2, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

IGFBP2, His, Cynomolgus

Insulin-like growth factor (IGF) binding protein 2 (IGFBP2) was discovered and identified as an IGF system regulator, controlling the distribution, function, and activity of IGFs in the pericellular space. IGFBP2 is a developmentally regulated gene that is highly expressed in embryonic and fetal tissues and markedly decreases after birth. Aberrant expression of IGFBP2 in cancer acts as a hub of an oncogenic network, integrating multiple cancer signaling pathways and serving as a potential therapeutic target for cancer treatment.
Z04816
¥72,752.00

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
IGFBP-2 (Gly33-Gln325)
Accession # A0A2K5WZA2		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 32.83 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 35-45 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • IGFBP2, His, Cynomolgus
    • IGFBP2, His, Cynomolgus

    The purity of IGFBP2, His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

  • IGFBP2, His, Cynomolgus
    • IGFBP2, His, Cynomolgus

    IGFBP2, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Insulin-like growth factor (IGF) binding protein 2 (IGFBP2) was discovered and identified as an IGF system regulator, controlling the distribution, function, and activity of IGFs in the pericellular space. IGFBP2 is a developmentally regulated gene that is highly expressed in embryonic and fetal tissues and markedly decreases after birth. Aberrant expression of IGFBP2 in cancer acts as a hub of an oncogenic network, integrating multiple cancer signaling pathways and serving as a potential therapeutic target for cancer treatment.
Synonyms IBP-2; IGFBP-2; BP2; AI255832; mIGFBP-2; IGFBP2; IGF-BP53

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.